Slide 1: FY23 Investor Presentation
FY23 Investor Presentation August 31, 2023 Mach7 Technologies ASX: M7T 1
Slide 2: Disclaimer "forward looking" statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date
Slide 3: Agenda
Agenda Business Overview FY23 Results Outlook • About Mach7 • Full-Year Highlights • Our Purpose • Record Sales Orders • Our Solution – Subscription weighting Appendices – New customer & partners • Our Scalable Framework • Major Contract Wins • Our AI Position • Revenue Composition • Our Markets • R
Slide 4: Business Overview
Business Overview Issued 18 February 2021, approved by the Board 4 4
Slide 5: About Mach7
About Mach7 Mach7 Technologies develops innovative image management and viewing solutions that form the core of an integrated enterprise imaging ecosystem. We give healthcare organisations the independence and flexibility to deploy our solutions according to their needs, either through individual pr
Slide 6: Our Purpose
Our Purpose Vision: We believe every healthcare organization should be an open and connected environment where patient information flows easily and can be viewed and accessed instantly. Mission: Our mission is to become the definitive technology partner that guides healthcare organisations through t
Slide 7: Our Solution – Enterprise Imaging Platform
Our Solution – Enterprise Imaging Platform Enterprise Data Management Enterprise Diagnostic Viewing Departmental Workflow Applications Vendor Neutral Archive eUnity Enterprise Diagnostic Viewer Reading & Departmental Workflow Allows customers to take control of their data Top-tier, KLAS-rated ZF
Slide 8: Our Scalable Framework
Our Scalable Framework Build on Existing Innovative Long-Term Allow Anyone to Join Work Technologies Scalability Builds upon the Provides a point of access Allows new and innovative Ensures variation around a substantial work done in to allow all types of technologies such as AI to broader set of us
Slide 9: Our AI Position
Our AI Position AI Market Dynamics: AI Ready - Data Storage, Management & Orchestration • According to Signify Research, the medical imaging AI Deployment, integration, data depth, data management and market was estimated at US$576 million and is forecast to data orchestration are key requirements f
Slide 10: Our Markets
Our Markets Diverse Market Segments and Global Footprint • Integrated Delivery Networks (IDNs) 165+ Customers in 15 Countries • US public health system (new market in FY24) • International hospital authorities • Regional and community hospital systems • Academic medical institutions • Medical resear
Slide 11: Our Customer Composition
Our Customer Composition Customer & Product Profile1 ClientOutlook Acquisition Impact $25.0 $20.0 Sales Orders TCV (A$M) • Acquisition Date: 14 July 2020 • Acquisition cost: $35M $15.0 • Revenue at Acquisition: $8M • Single product – eUnity Diagnostic Viewer $10.0 • Previously a tender partner with
Slide 12: Our Product Rankings
Our Product Rankings Best in KLAS 2023: Mach7 VNA Universal Viewer Segment (Vendor Neutral Archive) Ranked alongside large legacy #2 Placed #2 overall PACS vendors by KLAS including for second year in a row GE, Agfa and Philips. #1 Held the #1 spot for V12 of the Mach7 VNA being rolled most of CY 20
Slide 13: FY23 Results
FY23 Results Issued 18 February 2021, approved by the Board 13 13
Slide 14: Full Year Highlights
Full Year Highlights Record Sales Orders CARR3 ARR4 (TCV)1 Record Revenue $20.6M $17.0M run rate $40.3M $30.1M +$3.6M or 21% on PCP +$2.6M or 18% on PCP +$7.1M or 21% on PCP2 +$3.0M or 11% on PCP $24.8M at July 2023 $17.7M run rate July 2023 New contracts in EBITDA (adjusted)5 NPAT Strong financial
Slide 15: Record Sales Orders – Subscription Weighting
Record Sales Orders – Subscription Weighting Recurring revenue continues to be a feature of sales orders Sales Orders by Fee Type (TCV) Highlights: 45 • Record sales orders of $40.3M (TCV), up 21% on FY22 40 (+12% in constant currency1) and exceeding FY23 target of $36M. Sales orders are the best me
Slide 16: Record Sales Orders – New Customers and Partners
Record Sales Orders – New Customers and Partners New customers strengthen base for further growth FY23 Sales Orders by Order Type (TCV) Highlights: Add-on $3.2 M Expansion 8% New $9.6 M • New customer sales orders of $22.1M (55% of total sales orders) 24% $22.1 M represented 3 new logos: Akumin, Nuv
Slide 17: Major Contract Wins
Major Contract Wins New customers expand geographic and sectoral footprint FY23 Highlights – New Customers Buy Entire Enterprise Imaging Platform: • St. Paul’s Hospital HK - a private hospital with ~500 beds and more than 20 departments. The capital contract has TCV of $1.52M. • Nuvodia - a US radio
Slide 18: Revenue Composition
Revenue Composition Predominantly Recurring Highlights: FY 2023 FY 2022 % Change • Record revenue of $30.1M, up 11% on $27.1M in Enterprise Diagnostic 12.3 M 10.7 M 15% FY22 Viewing (eUnity) Enterprise Data • Revenue growth of $3.0M was impacted by the 17.8 M 16.4 M 9% Management (VNA)1 reclassifica
Slide 19: Recurring Revenue Trending Higher
Recurring Revenue Trending Higher Recurring revenue growth Highlights: Recurring Revenue: CARR v ARR 28 • Contracted Annual Recurring Revenue (CARR) of $20.6M, up 21% on $17.0M at June 2022. Post balance date, two significant contracts (VHA and DIA) improved 24 $7.1M CARR to $24.8M at July 2023. CAR
Slide 20: Strong Financials
Strong Financials NPAT uplift, healthy cash balance, no debt % Earnings FY23 FY22 Change Highlights: Revenues 30.1M 27.1 M +11% • Revenue growth of 11% ($3.0M) was impacted by reclassification of Akumin revenue to interest income as Distributor Fees (1.0M) (1.0M) - well as the timing and type of DIA
Slide 21: Corporate Update
Corporate Update Board Renewal Process Commenced: David Chambers will retire as Chair and Non-Executive Director of Mach7, effective from the close of the Company’s Annual General Meeting on 16 November 2023. David joined the Mach7 Board in August 2018 as an independent Non-Executive Director and wa
Slide 22: Outlook
Outlook Fragmentation Complex Renewal Sales pipeline opportunities opportunities opportunities opportunities Fragmented imaging market More complex reading Large FY24 renewal Largest and most diverse with long-time legacy environments and remote program will provide the pipeline of sales vendors los
Slide 23: Thank You
Thank You
Slide 24: Our Value Proposition
Our Value Proposition Fits Individual Needs Designed for the Enterprise Flexible Workflows We can fit into customers’ existing The foundation is in the enterprise, not Flexibility of workflows – with an intuitive technology infrastructure or adapt as it individual departmental systems. The Mach7 and
Slide 25: Our Differentiators
Our Differentiators • Enterprise First Strategy • ‘Top Performer’ Product Rankings • VNA backend data management solution • Mach7’s Viewer ranked #2 by independent designed and built for entire healthcare customer survey (KLAS Research). Features network rather than the radiology department include
Slide 26: KLAS – Defined
KLAS – Defined The Best in KLAS report recognises software and services companies who excel in helping healthcare professionals improve patient care. KLAS surveys’ healthcare IT customers (providers) throughout Best in KLAS is highly competitive and the calendar year and releases its final findings
Slide 27: Our Revenue Model
Our Revenue Model Revenue model caters to client funding needs Flexible revenue model allows for both subscription (“SaaS”) and capital licences, generally on 5-year terms. Equivalent Contracts: Capital Licence Subscription Licence Activity/Timing Fee Type Revenue Contribution Revenue Contribution R
Slide 28: Mach7 University
Mach7 University • Innovative solution to deliver training that fits work schedules and Course Catalog Examples lifestyles. • Clinical Studio Overview • eUnity 7.0 Overview • Unlimited attendees and unlimited access to informational videos, • eUnity Mammography • Hanging Protocols for Administrators
Slide 29: Our Leadership Team
Our Leadership Team Mike Lampron Dyan O’Herne David Madaffri Ravi Krishnan Chief Executive Chief Financial Chief Operating General Officer Officer Officer Manager, APAC Mike is the CEO of Mach7 Technologies. With over 20 years of Dyan is the Chief Financial Officer of Mach7 prior to which David is t
Slide 30: Our Board of Directors
Our Board of Directors David Chambers Mike Lampron Philippe Houssiau Outgoing Non-Executive Managing Director Non-Executive Director Chairman David has more than 30 years’ extensive experience in the Healthcare and Life Science Mike is the Chief Executive Officer and Managing Director of Mach7 Techn
Slide 31: Contact Us
Contact Us Investor Relations, Mach7: Rebecca Thompson +61 (0) 416 079 329 Rebecca.Thompson@mach7t.com Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer Issued 18 Febru